Validating Non-Invasive Biomarkers, Stratifying Patient Populations & Deciphering Game-Changing Combination Strategies to Translate Efficacious MASH Therapeutics into Clinical Success
MASH drug development is entering a pivotal new phase. As pharmaceutical and biotechnology companies advance differentiated therapies capable of delivering meaningful fibrosis improvement and long-term clinical benefit, growing investment in FGF-21 analogs, combination strategies, non-invasive biomarkers and AI-enabled pathology tools is transforming how therapies are discovered, developed and evaluated.
The 10th MASH Drug Development Summit was the industry's premier forum dedicated exclusively to advancing MASH therapeutics from discovery through clinical development. Bringing together senior leaders across discovery, translational science, clinical development, biomarkers and regulatory strategy, the meeting was designed to tackle the most pressing scientific and development challenges facing the field today.
Across three days of dedicated content, attendees explored how to improve translational confidence through human-relevant preclinical models, leverage non-invasive biomarkers and AI-enabled pathology to strengthen patient stratification, and advance differentiated therapeutic strategies capable of addressing disease heterogeneity and advanced fibrosis populations.
Attendees heard from experts representing Takeda, Pfizer, AstraZeneca, Madrigal Pharmaceuticals, Akero Therapeutics, Rivus Pharmaceuticals, Corcept Therapeutics, Cellarity, Insitro, Salubris Biotherapeutics, Harvard Medical School and more, as they shared the latest approaches shaping the future of MASH drug development.
Attendees joined 70+ senior discovery, translational, clinical and regulatory leaders to benchmark strategies, build valuable partnerships and gain practical insights that will help accelerate the development of efficacious therapies for patients living with MASH.
What I enjoyed most about the Summit was the collaborative atmosphere and knowledge sharing with different stakeholders working with one goal in mind to find therapies for MASH.
Senior Director - Medical & Boston Global Development, Novo Nordisk
I enjoyed connecting with the leaders and directors of all the companies. This is a great meeting to know drug development and what each company is thinking.
Managing Director & President, California Liver Research Institute
The pre-conference workshop day was very enjoyable, while the talks on basic research in the preclinical and translational sessions included some very exciting research.
Senior Fellow & Postdoctoral Researcher, Ghent University
2026 Official Partners
Attending Companies Included
Explore Related Events
Explore the Agenda
Reflect on the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Industry Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.